To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Adinazolam
Adinazolam (Deracyn) is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant[1] properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.[2] Additional recommended knowledge
PharmacologyAdinazolam produces inhibitory effects by binding to GABA receptors. This increases the effects of GABA. MetabolismAdinazolam was reported to have active metabolites in the August 1984 issue of The Journal of Pharmacy and Pharmacology.[3] The main metabolite is N-desmethyladinazolam.[4] The other two metabolites are alpha-hydroxyalprazolam and estazolam.[5] In the August 1986 issue of that same journal, Sethy, Francis and Day reported that proadifen inhibited the formation of N-desmethyladinazolam.[6] IndicationsAdinazolam is indicated as a treatment for anxiety and status epilepticus. References
Categories: Benzodiazepines | Hypnotics |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Adinazolam". A list of authors is available in Wikipedia. |